Thyroid Dysfunction and Ten-Year Incidence of Age-Related Macular Degeneration

被引:36
|
作者
Gopinath, Bamini
Liew, Gerald
Kifley, Annette
Mitchell, Paul
机构
[1] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia
[2] Univ Sydney, Westmead Inst, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
Blue Mountains Eye Study; thyroid dysfunction; age-related macular degeneration; older adults; incidence; OXIDATIVE STRESS; 5-YEAR INCIDENCE; RISK-FACTORS; MACULOPATHY; ANTIOXIDANT; PROGRESSION; PREVALENCE; AUSTRALIA; HORMONE; MODELS;
D O I
10.1167/iovs.16-19735
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. Epidemiologic evidence of a relationship between thyroid dysfunction and age-related macular degeneration (AMD) is inconsistent and unclear. We aimed to assess the prospective associations between serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) measurements, as well as thyroid dysfunction (hyperthyroidism and hypothyroidism) and incidence of AMD. METHODS. Categories of thyroid dysfunction were defined according to a serum TSH screen followed by serum FT4 assessment, and were available in 906 participants (aged 55+ years) at risk of AMD incidence (from 1997-1999 to 2007-2009). Continuous serum FT4 measures were available regardless of TSH screening results in 583 participants at risk of AMD incidence. Age-related macular degeneration was assessed from retinal photographs. RESULTS. Participants with overt hyperthyroidism compared to those with normal thyroid function at baseline had increased risk of developing any incident AMD, after adjusting for age, sex, smoking, fish consumption, and variants in AMD susceptibility genes (CFH and ARMS2): odds ratio (OR) 3.51 (95% confidence interval [CI] 1.16-10.65). Participants who reported current use of thyroxine (n = 67; 7.3%) versus those who were not current users (n = 839) had a 68% increased risk of incident AMD, multivariable-adjusted OR 1.68 (95% CI 1.01-2.82). Similarly, participants who had ever been on thyroxine medication (n = 77; 8.4%) compared to those who had never been on thyroxine (n = 829) also had a higher risk of any AMD, multivariable-adjusted OR 1.91 (95% CI 1.18-3.09). CONCLUSIONS. Overt hyperthyroidism was independently associated with an increased risk of incident AMD. Thyroxine usage in older adults was also positively associated with incidence of AMD.
引用
收藏
页码:5273 / 5277
页数:5
相关论文
共 50 条
  • [1] Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration
    Gillies, Mark C.
    Bhandari, Sanjeeb
    Wolff, Benjamin
    Arnold, Jennifer Joan
    Essex, Rohan W.
    Young, Stephanie
    Squirrell, David M.
    Barthelmes, Daniel
    Vuong Nguyen
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [2] Ten-Year Incidence of Fibrosis and Risk Factors for Its Development in Neovascular Age-Related Macular Degeneration
    Romano, Francesco
    Cozzi, Elisa
    Airaldi, Matteo
    Nassisi, Marco
    Viola, Francesco
    Aretti, Andrea
    Milella, Paolo
    Giuffrida, Francesco Pozzo
    Teo, Kelvin C. Y.
    Cheung, Chui Ming Gemmy
    Staurenghi, Giovanni
    Invernizzi, Alessandro
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2023, 252 : 170 - 181
  • [3] TEN-YEAR INCIDENCE OF AGE-RELATED MACULAR DEGENERATION ACCORDING TO DIABETIC RETINOPATHY CLASSIFICATION AMONG MEDICARE BENEFICIARIES
    Hahn, Paul
    Acquah, Kofi
    Cousins, Scott W.
    Lee, Paul P.
    Sloan, Frank A.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2013, 33 (05): : 911 - 919
  • [4] Ten-year survival trends of neovascular age-related macular degeneration at first presentation
    Arpa, Cristina
    Khalid, Hagar
    Chandra, Shruti
    Wagner, Siegfried
    Fasler, Katrin
    Faes, Livia
    Pooprasert, Pakinee
    Chopra, Reena
    Moraes, Gabriella
    Balaskas, Konstantinos
    Keane, Pearse A.
    Sivaprasad, Sobha
    Fu, Dun Jack
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2021, 105 (12) : 1688 - 1695
  • [5] Ten-year incidence and progression of age-related maculopathy
    Klein, R
    Klein, BEK
    Tomany, SC
    Meuer, SM
    Huang, GH
    OPHTHALMOLOGY, 2002, 109 (10) : 1767 - 1779
  • [6] Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions
    Gillies, Mark
    Arnold, Jennifer
    Bhandari, Sanjeeb
    Essex, Rohan W.
    Young, Stephanie
    Squirrell, David
    Vuong Nguyen
    Barthelmes, Daniel
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2020, 210 : 116 - 124
  • [7] TEN-YEAR RESULTS OF WET AGE-RELATED MACULAR DEGENERATION ANTI-VEGF TREATMENT
    Gerding, Heinrich
    Hefner, Lars
    Timmermann, Melanie
    Hurtikova, Katarina
    Somfai, Gabor
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [8] Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration
    Chandra, Shruti
    Arpa, Cristina
    Menon, Deepthy
    Khalid, Hagar
    Hamilton, Robin
    Nicholson, Luke
    Pal, Bishwanath
    Fasolo, Sandro
    Hykin, Philip
    Keane, Pearse A.
    Sivaprasad, Sobha
    EYE, 2020, 34 (10) : 1888 - 1896
  • [9] Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration
    Shruti Chandra
    Cristina Arpa
    Deepthy Menon
    Hagar Khalid
    Robin Hamilton
    Luke Nicholson
    Bishwanath Pal
    Sandro Fasolo
    Philip Hykin
    Pearse A. Keane
    Sobha Sivaprasad
    Eye, 2020, 34 : 1888 - 1896
  • [10] Ten-Year Follow-up of Age-Related Macular Degeneration in the Age-Related Eye Disease Study AREDS Report No. 36
    Chew, Emily Y.
    Clemons, Traci E.
    Agron, Elvira
    Sperduto, Robert D.
    SanGiovanni, John Paul
    Davis, Matthew D.
    Ferris, Frederick L., III
    JAMA OPHTHALMOLOGY, 2014, 132 (03) : 272 - 277